Recent updates on the role of microRNAs in prostate cancer

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Hassan, Oudai ^a   Ahmad, Aamir ^a   Sethi, Seema ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinogenesis; Metastasis; MiRNAs; Prostate Cancer

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC AGENT; FIBRONECTIN; GELATINASE A; GELATINASE B; K RAS PROTEIN; LET 7; MICRORNA; MIR 125B; MIR 143; MIR 145; MIR 200; MIR 200 S; MIR 200B; MIR 21; MIR 34A; MIR 375; MIRNA 15A; MIRNA 16; MITOGEN ACTIVATED PROTEIN KINASE; PLAKOGLOBIN; PROTEIN BCL 2; PROTEIN CCND 1; PROTEIN MCL 1; PROTEIN P53; STROMELYSIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PROGNOSIS; CANCER SCREENING; CANCER STEM CELL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; METASTASIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA BINDING; RNA DEGRADATION; RNA TRANSLATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; MALE; PROSTATE TUMOR;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS;

EID: 84858056340     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-9     Document Type: Review

References (90)

1. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, et al. PLoS One 2011 6 20341 10.1371/journal.pone.0020341 21647377
2. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Hao Y, Zhao Y, Zhao X, He C, Pang X, Wu TC, et al. Cancer Invest 2011 29 318 324 10.3109/07357907.2011.554477 21345070
3. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, et al. Int J Cancer 2011 130 611 621 21400514
4. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, et al. Mol Cell Biochem 2011 350 207 213 10.1007/s11010-010-0700-6 21197560
5. The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3'UTR. Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ, Genes Dev 2004 18 132 137 10.1101/gad.1165404 14729570 (Pubitemid 38141781)
6. Specificity of microRNA target selection in translational repression. Doench JG, Sharp PA, Genes Dev 2004 18 504 511 10.1101/gad.1184404 15014042 (Pubitemid 38372808)
7. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Lee RC, Feinbaum RL, Ambros V, Cell 1993 75 843 854 10.1016/0092-8674(93)90529-Y 8252621 (Pubitemid 24014542)
8. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Wightman B, Ha I, Ruvkun G, Cell 1993 75 855 862 10.1016/0092-8674(93)90530-4 8252622 (Pubitemid 24014543)
9. MicroRNA and Cancer: Tiny molecules with major implications. Vandenboom Ii TG, Li Y, Philip PA, Sarkar FH, Curr Genomics 2008 9 97 109 10.2174/138920208784139555 19440450 (Pubitemid 351888527)
10. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. Nature 2000 403 901 906 10.1038/35002607 10706289 (Pubitemid 30130993)
11. miRBase: microRNA sequences, targets and gene nomenclature. Griffiths-Jones S, Grocock RJ, Van DS, Bateman A, Enright AJ, Nucleic Acids Res 2006 34 140 D144 10.1093/nar/gkj112 16381832
12. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Ambros V, Cell 2003 113 673 676 10.1016/S0092-8674(03)00428-8 12809598 (Pubitemid 36724931)
13. MicroRNAs and prostate cancer. Coppola V, De MR, Bonci D, Endocr Relat Cancer 2010 17 1 F17 10.1677/ERC-09-0172 19779034
14. microRNA functions. Bushati N, Cohen SM, Annu Rev Cell Dev Biol 2007 23 175 205 10.1146/annurev.cellbio.23.090506.123406 17506695
15. Small non-coding RNAs in animal development. Stefani G, Slack FJ, Nat Rev Mol Cell Biol 2008 9 219 230 10.1038/nrm2347 18270516 (Pubitemid 351301826)
16. MicroRNAs: key regulators of stem cells. Gangaraju VK, Lin H, Nat Rev Mol Cell Biol 2009 10 116 125 10.1038/nrm2621 19165214
17. MicroRNAs: new regulators of immune cell development and function. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD, Nat Immunol 2008 9 839 845 10.1038/ni.f.209 18645592 (Pubitemid 352038302)
18. Viral and cellular messenger RNA targets of viral microRNAs. Cullen BR, Nature 2009 457 421 425 10.1038/nature07757 19158788
19. MicroRNAs and cardiac pathology. Latronico MV, Condorelli G, Nat Rev Cardiol 2009 6 419 429 19434076
20. MicroRNAs in neurodegeneration. Bushati N, Cohen SM, Curr Opin Neurobiol 2008 18 292 296 10.1016/j.conb.2008.07.001 18662781
21. The diverse functions of microRNAs in animal development and disease. Kloosterman WP, Plasterk RH, Dev Cell 2006 11 441 450 10.1016/j.devcel.2006.09. 009 17011485 (Pubitemid 44430905)
22. miRNA control of tumor cell invasion and metastasis. Baranwal S, Alahari SK, Int J Cancer 2010 126 1283 1290 19877123
23. MicroRNAs and prostate cancer. Pang Y, Young CY, Yuan H, Acta Biochim Biophys Sin (Shanghai) 2010 42 363 369 10.1093/abbs/gmq038
24. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al. PLoS One 2010 5 8697 10.1371/journal.pone.0008697 20084174
25. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Aqeilan RI, Calin GA, Croce CM, Cell Death Differ 2010 17 215 220 10.1038/cdd.2009.69 19498445
26. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. Proc Natl Acad Sci USA 2007 104 19983 19988 10.1073/pnas.0706641104 18056640
27. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. Oncogene 2008 27 4373 4379 10.1038/onc.2008.72 18372920 (Pubitemid 352010003)
28. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Mol Cancer 2006 5 24 10.1186/1476-4598-5-24 16784538 (Pubitemid 44376886)
29. MicroRNA expression profiling in prostate cancer. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T, Cancer Res 2007 67 6130 6135 10.1158/0008-5472.CAN-07-0533 17616669 (Pubitemid 47037493)
30. MicroRNA genes are transcribed by RNA polymerase II. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. EMBO J 2004 23 4051 4060 10.1038/sj.emboj. 7600385 15372072 (Pubitemid 39472426)
31. Processing of primary microRNAs by the Microprocessor complex. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ, Nature 2004 432 231 235 10.1038/nature03049 15531879 (Pubitemid 39545854)
32. The nuclear RNase III Drosha initiates microRNA processing. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. Nature 2003 425 415 419 10.1038/nature01957 14508493 (Pubitemid 37187272)
33. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. Bohnsack MT, Czaplinski K, Gorlich D, RNA 2004 10 185 191 10.1261/rna.5167604 14730017 (Pubitemid 38129823)
34. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Yi R, Qin Y, Macara IG, Cullen BR, Genes Dev 2003 17 3011 3016 10.1101/gad.1158803 14681208 (Pubitemid 38040764)
35. Role for a bidentate ribonuclease in the initiation step of RNA interference. Bernstein E, Caudy AA, Hammond SM, Hannon GJ, Nature 2001 409 363 366 10.1038/35053110 11201747 (Pubitemid 32151243)
36. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH, Genes Dev 2001 15 2654 2659 10.1101/gad.927801 11641272 (Pubitemid 32988876)
37. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Hammond SM, Bernstein E, Beach D, Hannon GJ, Nature 2000 404 293 296 10.1038/35005107 10749213 (Pubitemid 30163547)
38. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Schwarz DS, Hutvagner G, Haley B, Zamore PD, Mol Cell 2002 10 537 548 10.1016/S1097-2765(02)00651-2 12408822 (Pubitemid 35284172)
39. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Visvader JE, Lindeman GJ, Nat Rev Cancer 2008 8 755 768 10.1038/nrc2499 18784658
40. MicroRNA regulation of cancer stem cells and therapeutic implications. DeSano JT, Xu L, AAPS J 2009 11 682 692 10.1208/s12248-009-9147-7 19842044
41. MicroRNAs: regulators of oncogenesis and stemness. Papagiannakopoulos T, Kosik KS, BMC Med 2008 6 15 10.1186/1741-7015-6-15 18577221
42. Normal and leukemic human stem cells assayed in SCID mice. Dick JE, Semin Immunol 1996 8 197 206 10.1006/smim.1996.0025 8883142 (Pubitemid 26315854)
43. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE, Nat Med 2006 12 1167 1174 10.1038/nm1483 16998484 (Pubitemid 44527352)
44. Prospective identification of tumorigenic prostate cancer stem cells. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, Cancer Res 2005 65 10946 10951 10.1158/0008-5472.CAN-05-2018 16322242 (Pubitemid 41713363)
45. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Oncogene 2006 25 1696 1708 10.1038/sj.onc.1209327 16449977
46. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG, Cancer Res 2007 67 6796 6805 10.1158/0008-5472.CAN-07-0490 17638891 (Pubitemid 47105527)
47. miRNAs, cancer, and stem cell division. Croce CM, Calin GA, Cell 2005 122 6 7 10.1016/j.cell.2005.06.036 16009126 (Pubitemid 40977933)
48. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Melton C, Judson RL, Blelloch R, Nature 2010 463 621 626 10.1038/nature08725 20054295
49. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. Cell 2007 131 1109 1123 10.1016/j.cell.2007.10.054 18083101 (Pubitemid 350235025)
50. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Cell 2009 138 592 603 10.1016/j.cell.2009.07.011 19665978
51. Human embryonic stem cells express a unique set of microRNAs. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, et al. Dev Biol 2004 270 488 498 10.1016/j.ydbio.2004.02.019 15183728 (Pubitemid 38748567)
52. A microRNA component of the p53 tumour suppressor network. He L, He X, Lim LP, De SE, Xuan Z, Liang Y, et al. Nature 2007 447 1130 1134 10.1038/nature05939 17554337 (Pubitemid 47014436)
53. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Mol Cell 2007 26 731 743 10.1016/j.molcel.2007.05.017 17540598 (Pubitemid 46856247)
54. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Mol Cell 2007 26 745 752 10.1016/j.molcel.2007.05.010 17540599 (Pubitemid 46856245)
55. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. Curr Biol 2007 17 1298 1307 10.1016/j.cub.2007.06.068 17656095 (Pubitemid 47176893)
56. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Cell Cycle 2007 6 1586 1593 10.4161/cc.6.13.4436 17554199 (Pubitemid 47327945)
57. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. Nat Med 2011 17 211 215 10.1038/nm.2284 21240262
58. Epithelial-mesenchymal transitions in development and disease. Thiery JP, Acloque H, Huang RY, Nieto MA, Cell 2009 139 871 890 10.1016/j.cell.2009.11.007 19945376
59. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, et al. PLoS One 2011 6 21650 10.1371/journal. pone.0021650 21747944
60. The basics of epithelial-mesenchymal transition. Kalluri R, Weinberg RA, J Clin Invest 2009 119 1420 1428 10.1172/JCI39104 19487818
61. The role of microRNAs in metastasis and epithelial-mesenchymal transition. Bracken CP, Gregory PA, Khew-Goodall Y, Goodall GJ, Cell Mol Life Sci 2009 66 1682 1699 10.1007/s00018-009-8750-1 19153653
62. Biomarkers for epithelial-mesenchymal transitions. Zeisberg M, Neilson EG, J Clin Invest 2009 119 1429 1437 10.1172/JCI36183 19487819
63. MicroRNAs: Targets of Interest in Breast Cancer Research. Ahmad A, Ali AS, Ali S, Wang Z, Kong D, Sarkar FH, MicroRNA: Expression, Detection and Therapeutic Strategies New York: Nova Publishers, Mulligan JA, 2011 59 78
64. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Int J Cancer 2010 126 1166 1176 19676045
65. Widespread deregulation of microRNA expression in human prostate cancer. Ozen M, Creighton CJ, Ozdemir M, Ittmann M, Oncogene 2008 27 1788 1793 10.1038/sj.onc.1210809 17891175 (Pubitemid 351380263)
66. The activity and expression of microRNAs in prostate cancers. Fu X, Xue C, Huang Y, Xie Y, Li Y, Mol Biosyst 2010 6 2561 2572 10.1039/c0mb00100g 20957285
67. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, et al. PLoS One 2009 4 7542 10.1371/journal.pone.0007542 19855844
68. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. Micalizzi DS, Farabaugh SM, Ford HL, J Mammary Gland Biol Neoplasia 2010 15 117 134 10.1007/s10911-010-9178-9 20490631
69. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al. Stem Cells 2009 27 1712 1721 10.1002/stem.101 19544444
70. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al. PLoS One 2010 5 12445 10.1371/journal.pone.0012445 20805998
71. Circulating miRNAs are correlated with tumor progression in prostate cancer. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Int J Cancer 2011 128 608 616 10.1002/ijc.25376 20473869
72. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L, et al. Oncogene 2011 30 4231 4242 10.1038/onc.2011.140 21532615
73. Most mammalian mRNAs are conserved targets of microRNAs. Friedman RC, Farh KK, Burge CB, Bartel DP, Genome Res 2009 19 92 105 18955434
74. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, et al. Cancer Res 2011 71 3400 3409 10.1158/0008-5472.CAN-10-0965 21389093
75. miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC, Int J Cancer 2010 DOI: 10.1002/ijc.25753
76. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P, Cancer Res 2009 69 3356 3363 10.1158/0008-5472.CAN-08-4112 19351832
77. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, et al. J Biol Chem 2007 282 23716 23724 10.1074/jbc.M701805200 17569667 (Pubitemid 47311902)
78. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Zheng C, Yinghao S, Li J, Med Oncol 2011 DOI: 10.1007/s12032-011-9934-8
79. miR-21-mediated tumor growth. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY, Oncogene 2007 26 2799 2803 10.1038/sj.onc.1210083 17072344 (Pubitemid 46663837)
80. miR-21 as a key regulator of oncogenic processes. Selcuklu SD, Donoghue MT, Spillane C, Biochem Soc Trans 2009 37 918 925 10.1042/BST0370918 19614619
81. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Li T, Li D, Sha J, Sun P, Huang Y, Biochem Biophys Res Commun 2009 383 280 285 10.1016/j.bbrc.2009.03.077 19302977
82. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al. Cancer Res 2009 69 7165 7169 10.1158/0008-5472.CAN-09-1448 19738047
83. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, et al. PLoS One 2011 6 17850 10.1371/journal.pone.0017850 21408027
84. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. Lee YS, Kim HK, Chung S, Kim KS, Dutta A, J Biol Chem 2005 280 16635 16641 10.1074/jbc.M412247200 15722555 (Pubitemid 41389120)
85. MicroRNAs and their potential for translation in prostate cancer. Vere White RW, Vinall RL, Tepper CG, Shi XB, Urol Oncol 2009 27 307 311 10.1016/j.urolonc.2009.01.004 19414119
86. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, et al. Cancer Res 2010 70 3606 3617 10.1158/0008-5472.CAN-09-4598 20388782
87. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH, Am J Transl Res 2010 3 28 47 21139804
88. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, et al. J Cell Physiol 2011 DOI:10.1002/jcp.24036
89. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Ali S, Ahmad A, Aboukameel A, Bao B, Padhye S, Philip PA, et al. Cancer Lett 2012 DOI:10.1016/j.canlet.2012.01.013
90. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Yu Y, Kanwar SS, Patel BB, Oh PS, Nautiyal J, Sarkar FH, et al. Carcinogenesis 2012 33 68 76 10.1093/carcin/bgr246 22072622